CLINICAL_TRIALS
trial_result
· 2016-10-11
Clinical Trial Update: Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) [Phase 2]
Summary
A Phase 2 clinical trial evaluating GLPG1837 in cystic fibrosis patients with the S1251N mutation has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Galapagos NV | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED